Cited by 865Bone health and treatmentsBone health and osteoporosis researchBone Metabolism and Diseases

The DOI matches its Crossref record; 71 of the 75 references it cites were found in a registry or an index.

Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite

Nancollas, G.H., Tang, R., Phipps, R.J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R.G.G., Ebetino, F.H.·2006·Bone

DOI 10.1016/j.bone.2005.05.003

Open this paper in CoChat — free account

Abstract

Bisphosphonates are now the most widely used drugs for diseases associated with increased bone resorption, such as osteoporosis. Although bisphosphonates act directly on osteoclasts, and interfere with specific biochemical processes such as protein prenylation, their ability to adsorb to bone mineral also contributes to their potency and duration of action. The aim of the present study was to compare the binding affinities for hydroxyapatite (HAP) of 6 bisphosphonates currently used clinically and to determine the effects of these bisphosphonates on other mineral surface properties including zeta potential and interfacial tension. Affinity constants (K(L)) for the adsorption of bisphosphonates were calculated from kinetic studies on HAP crystal growth using a constant composition method at 37 degrees C and at physiological ionic strength (0.15 M). Under conditions likely to simulate bisphosphonate binding onto bone, there were significant differences in K(L) among the bisphosphonates for HAP growth (pH 7.4) with a rank order of zoledronate > alendronate > ibandronate > risedronate > etidronate > clodronate. The measurements of zeta potential show that the crystal surface is modified by the adsorption of bisphosphonates in a manner best explained by molecular charges related to the protonation of their side-chain moieties, with risedronate showing substantial differences from alendronate, ibandronate, and zoledronate. The studies of the solid/liquid interfacial properties show additional differences among the bisphosphonates that may influence their mechanisms for binding and inhibiting crystal growth and dissolution. The observed differences in kinetic binding affinities, HAP zeta potentials, and interfacial tension are likely to contribute to the biological properties of the various bisphosphonates. In particular, these binding properties may contribute to differences in uptake and persistence in bone and the reversibility of effects. These properties, therefore, have potential clinical implications that may be important in understanding differences among potent bisphosphonates, such as the apparently more prolonged duration of action of alendronate and zoledronate compared with the more readily reversible effects of etidronate and risedronate.

Integrity signals

Registry

Crossref · 10.1016/j.bone.2005.05.003

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Dynamics of Capillary Flow
Washburn, E. W. (1921) · Physical Review · doi:10.1103/physrev.17.273 · Cited by 7,202
Zeta Potential in Colloid Science
(1981) · Elsevier eBooks · doi:10.1016/c2013-0-07389-6 · Cited by 2,349
Interfacial Forces in Aqueous Media
van Oss, C. J. (2006) · CRC Press eBooks · doi:10.1201/9781420015768 · Cited by 1,921
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
Black, D. M., Greenspan, S. L., Ensrud, K. E., Palermo, L., McGowan, J., Lang, T., Garnero, P., Bouxsein, M., Bilezikian, J. P., & Rosen, C. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031975 · Cited by 1,168
Structure-Activity Relationships for Inhibition of Farnesyl Diphosphate Synthase in Vitro and Inhibition of Bone Resorption in Vivo by Nitrogen-Containing Bisphosphonates
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Self-citation
Interfacial Forces in Aqueous Media
Visser, H. (1995) · Powder Technology · doi:10.1016/0032-5910(95)90005-5 · Cited by 884
Kinetics of Precipitation.
Liotta, S. (1965) · Journal of the American Chemical Society · doi:10.1021/ja01084a069 · Cited by 881
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z. D., Richardson, P. A., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 870
Bisphosphonates: from the laboratory to the clinic and back again
Russell, R. G. G., & Rogers, M. J. (1999) · Bone · doi:10.1016/s8756-3282(99)00116-7 · Cited by 838
Self-citation

Flagged first, then by citations

Show all 75 references

4 of the 75 references couldn’t be matched to a known paper.

Research works printed but not linked: 9

Benedict J.J., The physical chemistry of the diphosphonates—Its relationship to their medical activity. In: Donath A., Courvoisier B., editors. Symposium Cemo, Centre D'Etude des Maladies Osteoarticulatires de Geneve (IV), 1–19. 1982. Geneva, Editions Medicine et Hygiene. Diphosphonates and Bone;1990:7–9.
Sunberg, 1991, Designing drugs for stronger bones, Chemtech, 21, 304
Ebetino, 1998, Mechanisms of action of etidronate and other bisphosphonates, Rev. Contemp. Pharmacother., 9, 233
Traube, 1927, Solubility and surface tension, Ber, 60B, 1808
Semenchenko, 1934, Solubility and surface tension, Uspekhi Khimii, 3, 710
Bagda, 1978, The relation between surface tension and the solubility parameter in liquids, Farbe Lack, 84, 212
Leu, 2004, Relative binding affinities of bisphosphonates for human bone, Bone, 34, S62
Christiansen, 2003, Comparison of risedronate and alendronate pharmacokinetics at clinical doses, Osteoporos Int., 14, S38
Watts, 2004, Treatment discontinuation effects on bone turnover and BMD with risedronate, Bone, 34, S99

Sorted by citations

Items 301–400 of 865

Anabolic and antiresorptive actions of locally delivered bisphosphonates for bone repair
Qayoom, I., Raina, D. B., Širka, A., Tarasevičius, Š., Tägil, M., Kumar, A., & Lidgren, L. (2018) · Bone and Joint Research · doi:10.1302/2046-3758.710.bjr-2018-0015.r2 · Cited by 34
Relative binding affinity of carboxylate-, phosphonate-, and bisphosphonate-functionalized gold nanoparticles targeted to damaged bone tissue
Ross, R. D., Cole, L. E., & Roeder, R. K. (2012) · Journal of Nanoparticle Research · doi:10.1007/s11051-012-1175-z · Cited by 34
The effect of osteoporosis treatments on fatigue properties of cortical bone tissue
Brock, G. R., Chen, J. T., Ingraffea, A. R., MacLeay, J., Pluhar, G. E., Boskey, A. L., & van der Meulen, M. C. H. (2015) · Bone Reports · doi:10.1016/j.bonr.2014.10.004 · Cited by 33
Bisphosphonate-Related Osteonecrosis of the Jaw and Oral Microbiome: Clinical Risk Factors, Pathophysiology and Treatment Options
Jelin-Uhlig, S., Weigel, M., Ott, B., Imirzalioglu, C., Howaldt, H., Böttger, S., & Hain, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158053 · Cited by 42
Covalent modification of calcium hydroxyapatite surface by grafting phenyl phosphonate moieties
Aissa, A., Debbabi, M., Gruselle, M., Thouvenot, R., Gredin, P., Traksmaa, R., & Tõnsuaadu, K. (2007) · Journal of Solid State Chemistry · doi:10.1016/j.jssc.2007.05.016 · Cited by 33
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers
Anastasilakis, A. D., Pοlyzos, S. A., Efstathiadou, Z. A., Savvidis, M. S., Sakellariou, G. T., Παπαθεοδώρου, Α., Kokkoris, P., & Makras, P. (2015) · Metabolism · doi:10.1016/j.metabol.2015.06.018 · Cited by 33
Quercetin and alendronate multi‐functionalized materials as tools to hinder oxidative stress damage
Forte, L., Torricelli, P., Boanini, E., Rubini, K., Fini, M., & Bigi, A. (2017) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36192 · Cited by 33
Enhanced Affinity Bifunctional Bisphosphonates for Targeted Delivery of Therapeutic Agents to Bone
Yewle, J. N., Puleo, D. A., & Bachas, L. G. (2011) · Bioconjugate Chemistry · doi:10.1021/bc2003132 · Cited by 33
Basic fibroblast growth factor suspended in Matrigel improves titanium implant fixation in ovariectomized rats
Gao, Y., Zhu, S., Luo, E., Li, J., Feng, G., & Hu, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.05.032 · Cited by 33
Bisphosphonate Drug Holiday: Choosing Appropriate Candidates
Ro, C., & Cooper, O. B. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0129-9 · Cited by 32
Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone
Merlotti, D., Rendina, D., Gennari, L., Mossetti, G., Gianfrancesco, F., Martini, G., FILIPPO, G. D., Avanzati, A., Franci, B., Campagna, M. S., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.237 · Cited by 32
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women
Frost, M. L., Siddique, M., Blake, G. M., Moore, A. E. B., Marsden, P. K., Schleyer, P. J., Eastell, R., & Fogelman, I. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1805-9 · Cited by 32
Bisphosphonates: Pharmacology and Clinical Approach to Their Use in Equine Osteoarticular Diseases
Soto, S., & Barbará, A. C. (2014) · Journal of Equine Veterinary Science · doi:10.1016/j.jevs.2014.01.009 · Cited by 31
Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover
Peris, P., Torra, M., Olivares, V., Reyes, R., Monegal, A., Martinez-Ferrer, A., & Guañabens, N. (2011) · Bone · doi:10.1016/j.bone.2011.06.027 · Cited by 31
Crystalline Calcium Alendronate Obtained by Octacalcium Phosphate Digestion: A New Chance for Local Treatment of Bone Loss Diseases?
Boanini, E., Torricelli, P., Gazzano, M., Fini, M., & Bigi, A. (2013) · Advanced Materials · doi:10.1002/adma.201301129 · Cited by 31
Hydroxyapatite functionalization to trigger adsorption and release of risedronate
Forte, L., Sarda, S., Combes, C., Brouillet, F., Gazzano, M., Marsan, O., Boanini, E., & Bigi, A. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.09.055 · Cited by 31
Zoledronic Acid
Deeks, E. D., & Perry, C. M. (2008) · Drugs & Aging · doi:10.2165/0002512-200825110-00007 · Cited by 31
Customizable Silk Fibroin-Based Hydrogel Fibrous Scaffold for On-Demand Multifaceted Tissue Repair
He, X., Wang, R., Liu, X., Peng, R., Zhou, B., Wang, L., Wei, X., Wang, S., Bai, J., Feng, Q., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c03283 · Cited by 30
Doses effects of zoledronic acid on mineral apatite and collagen quality of newly-formed bone in the rat's calvaria defect
Olejnik, C., Falgayrac, G., During, A., Cortet, B., & Penel, G. (2016) · Bone · doi:10.1016/j.bone.2016.05.002 · Cited by 31
Role of local alendronate delivery on the osseointegration of implants: a systematic review and meta-analysis
Kellesarian, S. V., Abduljabbar, T. S., Vohra, F. A., Malignaggi, V. R., Malmström, H., Romanos, G. E., & Javed, F. (2017) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2017.03.009 · Cited by 30
Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function
Elsayed, R., Abraham, P., Awad, M. E., Kurago, Z., Baladhandayutham, B., Whitford, G. M., Pashley, D. H., McKenna, C. E., & Elsalanty, M. E. (2018) · Bone · doi:10.1016/j.bone.2018.01.030 · Cited by 31
Minodronate for the treatment of osteoporosis
Ohishi, T., & Matsuyama, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s149236 · Cited by 32
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
Ikesue, H., Doi, K., Morimoto, M., Hirabatake, M., Muroi, N., Yamamoto, S., Takenobu, T., & Hashida, T. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04262-w · Cited by 30
A facile synthesis of ibandronate modified hydroxyapatite renewable nanomaterials for simultaneous removal of Cu2+/Pb2+ and chlortetracycline: Experimental design and adsorption mechanism study
Ma, J., Xia, M., Belver, C., Zhang, Y., & Wang, F. (2022) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2022.132173 · Cited by 30
Increases in Hip and Spine Bone Mineral Density are Predictive for Vertebral Antifracture Efficacy with Ibandronate
Miller, P. D., Delmas, P. D., Huss, H., Patel, K., Schimmer, R. C., Adami, S., & Recker, R. R. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9403-y · Cited by 30
Epidemiology of Bisphosphonate-Related Osteonecrosis of the Jaws: The Utility of a National Registry
Gliklich, R. E., & Wilson, J. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.005 · Cited by 30
The effect of alendronate doped calcium phosphates on bone cells activity
Boanini, E., Torricelli, P., Gazzano, M., Fini, M., & Bigi, A. (2012) · Bone · doi:10.1016/j.bone.2012.07.020 · Cited by 30
Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget’s disease
Pοlyzos, S. A., Anastasilakis, A. D., Litsas, I., Efstathiadou, Z. A., Kita, M. D., Arsos, G. A., Moralidis, E., Παπαθεοδώρου, Α., & Terpos, E. (2010) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-010-0198-8 · Cited by 29
Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(ε-caprolactone)/hydroxyapatite microspheres
Chen, J., Luo, Y., Hong, L., Ling, Y., Pang, J., Fang, Y., Wei, K., & Gao, X. (2011) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-011-4232-8 · Cited by 29
Biomimetic gelatin–octacalcium phosphate core–shell microspheres
Boanini, E., & Bigi, A. (2011) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2011.06.061 · Cited by 29
Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis
Zhou, W., Liu, Y., Guo, X., Yang, H., Xu, Y., & Geng, D. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05005-7 · Cited by 29
Comparative Fracture Risk During Osteoporosis Drug Holidays After Long-Term Risedronate Versus Alendronate Therapy
Hayes, K. N., Brown, K. A., Cheung, A. M., Kim, S. A., Juurlink, D. N., & Cadarette, S. M. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2512 · Cited by 29
Research progress of bone-targeted drug delivery system on metastatic bone tumors
Hu, B., Zhang, Y., Zhang, G., Li, Z., Jing, Y., Yao, J. P., & Sun, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.034 · Cited by 29
In vivo study and thermodynamic investigation of two lanthanum complexes, La(dpp) 3 and La(XT), for the treatment of bone resorption disorders
Cawthray, J. F., Weekes, D. M., Sivak, O., Creagh, A. L., Ibrahim, F., Iafrate, M., Haynes, C. A., Wasan, K. M., & Orvig, C. (2015) · Chemical Science · doi:10.1039/c5sc01767j · Cited by 29
An In Vitro Assessment of Fibroblast and Osteoblast Response to Alendronate-Modified Titanium and the Potential for Decreasing Fibrous Encapsulation
Hu, X., Neoh, K. G., Shi, Z., Kang, E. T., & Wang, W. (2013) · Tissue Engineering Part A · doi:10.1089/ten.tea.2012.0218 · Cited by 29
Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea
Lee, S. H., Gong, H. S., Kim, T., Park, S.-Y., Shin, J., Cho, S. W., & Byun, D. W. (2015) · Journal of Bone Metabolism · doi:10.11005/jbm.2015.22.4.167 · Cited by 29
Hydroxyapatite with Permanent Electrical Polarization: Preparation, Characterization, and Response against Inorganic Adsorbates
Rivas, M., del Valle, L. J., Armelin, E. A., Bertrán, O., Turón, P., Puiggalı́, J., & Alemán, C. (2018) · ChemPhysChem · doi:10.1002/cphc.201800196 · Cited by 29
Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget’s disease of bone
Avramidis, A., Pοlyzos, S. A., Moralidis, E., Arsos, G. A., Efstathiadou, Z. A., Karakatsanis, K., Grollios, G., & Kita, M. D. (2008) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-008-0852-6 · Cited by 29
Modification of Hydroxyapatite with Ion-Selective Complexants: 1-Hydroxyethane-1,1-diphosphonic Acid
Daniels, Y. C., Lyczko, N., Nzihou, A., & Alexandratos, S. D. (2014) · Industrial & Engineering Chemistry Research · doi:10.1021/ie504181z · Cited by 28
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg
Abelson, A. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x260899 · Cited by 28
Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort
Misof, B. M., Roschger, P., Gabriel, D., Paschalis, E. P., Eriksen, E. F., Recker, R. R., Gasser, J. A., & Klaus Klaushofer, A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1780 · Cited by 28
Anticancer evaluation and drug delivery of new palladium(II) complexes based on the chelate of alendronate onto hydroxyapatite nanoparticles
Fathy, A. A., Butler, I. S., Elrahman, M. A., Jean‐Claude, B. J., & Mostafa, S. I. (2017) · Inorganica Chimica Acta · doi:10.1016/j.ica.2017.12.015 · Cited by 28
The effects of bisphosphonates on osteoporotic patients after lumbar fusion: a meta-analysis
Liu, W., Zhao, W., Shen, P., & Zhang, F.-J. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s164548 · Cited by 28
Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing’s syndrome
Tauchmanovà, L., Guerra, E., Pivonello, R., Martino, M. C. D., Leo, M. D., Caggiano, F., Lombardi, G., & Colao, A. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03346473 · Cited by 28
An integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens, G. M., Jackson, R. D., & Lewiecki, E. M. (2007) · PubMed · Cited by 28
Atypical Femoral fractures: A Review of the Literature
Desai, P., Vyas, P. A., & Lane, J. M. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0167-y · Cited by 27
Local administration of alendronate reduced peri‐tunnel bone loss and promoted graft‐bone tunnel healing with minimal systemic effect on bone in contralateral knee
Lui, P. P. Y., Lee, Y. W., Mok, T. Y., & Cheuk, Y. (2013) · Journal of Orthopaedic Research® · doi:10.1002/jor.22442 · Cited by 27
Anti-Osteoporotic Drug Release from Ordered Mesoporous Bioceramics: Experiments and Modeling
Manzano, M., Lamberti, G., Galdi, I., & Vallet‐Regí, M. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-011-9688-9 · Cited by 27
Nitrogen-containing bisphosphonates modulate the antigenic profile and inhibit the maturation and biomineralization potential of osteoblast-like cells
Manzano‐Moreno, F. J., Ramos‐Torrecillas, J., Luna‐Bertos, E. D., Reyes‐Botella, C., Ruíz, C., & García‐Martínez, O. (2014) · Clinical Oral Investigations · doi:10.1007/s00784-014-1309-z · Cited by 27
Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions
Newman, C. L., Chen, N. X., Smith, E., Smith, M. S., Brown, D. M., Moe, S. M., & Allen, M. R. (2015) · Bone · doi:10.1016/j.bone.2015.04.021 · Cited by 27
Zoledronic Acid Versus Alendronate In The Treatment of Children With Osteogenesis Imperfecta: A 2-Year Clinical Study
Lv, F., Liu, Y., Xu, X., Song, Y., Li, L., Jiang, Y., Wang, O., Xia, W., Xing, X., & Li, M. (2018) · Endocrine Practice · doi:10.4158/ep171910.or · Cited by 27
Ibandronate: Pharmacology and preclinical studies
Russell, R. G. G. (2006) · Bone · doi:10.1016/j.bone.2006.01.151 · Cited by 27
Self-citation
Adsorption on Apatitic Calcium Phosphates: Applications to Drug Delivery
Errassifi, F., Menbaoui, A., Autefage, H., Benaziz, L., Ouizat, S., Santran, V., Sarda, S., Lebugle, A., Combes, C., Barroug, A., et al. (2010) · Ceramic transactions /Ceramic transactions · doi:10.1002/9780470909898.ch16 · Cited by 27
Updates on Paget’s Disease of Bone
Choi, Y. J., Sohn, Y. B., & Chung, Y. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1575 · Cited by 26
Biomaterials for orthopedic diagnostics and theranostics
Ackun‐Farmmer, M. A., Overby, C. T., Haws, B. E., Choe, R., & Benoit, D. S. W. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100308 · Cited by 28
Guidelines on pain management
(1994) · Nursing Standard · doi:10.7748/ns.8.47.10.s29 · Cited by 26
The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts
Enjuanes, A., Ruiz-Gaspà, S., Peris, P., Ozalla, D., Álvarez, L., Combalía, A., de Osaba, M. J. M., Monegal, A., Parés, A. R., & Guañabens, N. (2009) · Endocrine · doi:10.1007/s12020-009-9285-9 · Cited by 26
A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting
Meckel, M., Kubíček, V., Hermann, P., Miederer, M., & Rösch, F. (2016) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2016.07.009 · Cited by 26
Types of ceramics
Drouet, C., Leriche, A., Hampshire, S., Kashani, M., Stamboulis, A. G., Iafisco, M., & Tampieri, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-100881-2.00002-6 · Cited by 26
Star-shaped poly(oligoethylene glycol) copolymer-based gels: Thermo-responsive behaviour and bioapplicability for risedronate intranasal delivery
Soliman, M. E., Elmowafy, E. M., Casettari, L., & Alexander, C. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.03.053 · Cited by 26
Recent advances in functional nanostructured materials for bone-related diseases
Li, A., Xie, J., & Li, J. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb02812e · Cited by 26
Organically modified porous hydroxyapatites: A comparison between alkylphosphonate grafting and citrate chelation
Hammari, L. E., Marroun, H., Laghzizil, A., Saoiabi, A., Roux, C., Livage, J., & Coradin, T. (2008) · Journal of Solid State Chemistry · doi:10.1016/j.jssc.2008.01.030 · Cited by 26
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease
Lawson, M. A., Coulton, L. A., Ebetino, F. H., Vanderkerken, K., & Croucher, P. I. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.157 · Cited by 26
Self-citation
Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs)
Lolli, M. L., Rolando, B., Tosco, P., Chaurasia, S., Stilo, A. D., Lazzarato, L., Gorassini, E., Ferracini, R., Oliaro‐Bosso, S., Fruttero, R., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.02.058 · Cited by 25
Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties
Hassler, N., Gamsjaeger, S., Hofstetter, B., Brozek, W., Klaushofer, K., & Paschalis, E. P. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2929-5 · Cited by 25
Physicochemical bisphosphonate immobilization on titanium dioxide thin films surface by UV radiation for bio-application
Bronze‐Uhle, É. S., Dias, L. F. G., Trino, L. D., Matos, A. A., de Oliveira, R. C., & Lisboa‐Filho, P. N. (2018) · Surface and Coatings Technology · doi:10.1016/j.surfcoat.2018.09.038 · Cited by 25
Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders
Sawamoto, K., Álvarez, J. V., Herreño, A. M., Otero-Espinar, F. J., Couce, M. L., Alméciga-Díaz, C. J., & Tomatsu, S. (2020) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00620-4 · Cited by 25
Discovering inhibitor molecules for pathological crystallization of CaOx kidney stones from natural extracts of medical herbs
Li, S., Macaringue, E. G. J., Zhou, D., Shi, P., Tang, W., & Gong, J. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114733 · Cited by 26
Calcium and Strontium Coordination Polymers as Controlled Delivery Systems of the Anti-Osteoporosis Drug Risedronate and the Augmenting Effect of Solubilizers
Vassaki, M., Kotoula, C., Turhanen, P. A., Choquesillo‐Lazarte, D., & Demadis, K. D. (2021) · Applied Sciences · doi:10.3390/app112311383 · Cited by 25
Intramuscular Neridronate in Postmenopausal Women with Low Bone Mineral Density
Adami, S., Gatti, D., Bertoldo, F., Sartori, L., Munno, O. D., Filipponi, P., Marcocci, C., Frediani, B., Palummeri, E., Fiore, C. E., et al. (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9179-5 · Cited by 25
Optimal increase in bone mass by continuous local infusion of alendronate during distraction osteogenesis in rabbits
Abbaspour, A., Takahashi, M., Sairyo, K., Takata, S., Yukata, K., Inui, A., & Yasui, N. (2009) · Bone · doi:10.1016/j.bone.2009.01.007 · Cited by 25
Inhibition of Pathological Mineralization of Calcium Phosphate by Phosphorylated Osteopontin Peptides through Step-Specific Interactions
Li, S., Wu, S., Nan, D., Zhang, W., & Wang, L. (2014) · Chemistry of Materials · doi:10.1021/cm502111v · Cited by 25
Diagnosis and treatment of Paget’s disease of bone
Muschitz, C., Feichtinger, X., Haschka, J., & Kocijan, R. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0502-x · Cited by 24
Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Dash, A. K., Das, T., & Knapp, F. F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190201142814 · Cited by 24
Intravenous Ibandronate Acutely Reduces Bone Hyperresorption in Chronic Critical Illness
Via, M. A., Potenza, M. V., Hollander, J. M., Liu, X., Peng, Y., Li, J., Sun, L., Zaidi, M., & Mechanick, J. I. (2011) · Journal of Intensive Care Medicine · doi:10.1177/0885066611402156 · Cited by 24
Comparative physicochemical properties and cytotoxicity of polyphosphoester ionomers with bisphosphonates
Iwasaki, Y., Katayama, K., Yoshida, M., Yamamoto, M., & Tabata, Y. (2012) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2012.710823 · Cited by 24
The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation
Weivoda, M. M., & Hohl, R. J. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23087 · Cited by 24
First-principles study of structural and surface properties of (001) and (010) surfaces of hydroxylapatite and carbonated hydroxylapatite
Ulian, G., Moro, D., & Valdré, G. (2016) · Journal of Applied Crystallography · doi:10.1107/s160057671601390x · Cited by 23
A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw
Bullock, G. A., Miller, C. A., McKechnie, A. J., & Hearnden, V. L. (2022) · Frontiers in Oral Health · doi:10.3389/froh.2021.822411 · Cited by 24
Alendronate-Eluting Biphasic Calcium Phosphate (BCP) Scaffolds Stimulate Osteogenic Differentiation
Kim, S. E., Yun, Y.-P., Lee, D.-W., Kang, E. Y., Jeong, W. J., Lee, B.-R., Jeong, M. S., Kim, H. J., Park, K., & Song, H. (2015) · BioMed Research International · doi:10.1155/2015/320713 · Cited by 23
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment
Ironside, M. S., Duer, M. J., Reid, D. G., & Byard, S. J. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.05.013 · Cited by 23
Effect of Dosing Interval Duration of Intermittent Ibandronate Treatment on the Healing Process of Femoral Osteotomy in a Rat Fracture Model
Manabe, T., Mori, S., Mashiba, T., Kaji, Y., Iwata, K., Komatsubara, S., & Yamamoto, T. (2012) · Calcified Tissue International · doi:10.1007/s00223-011-9563-4 · Cited by 23
Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
Inderjeeth, C. A., Glendenning, P., Ratnagobal, S., Inderjeeth, D. C., & Ondhia, C. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s73944 · Cited by 23
Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy
Hofstetter, B., Gamsjaeger, S., Varga, F., Dobnig, H., Stepan, J. J., Petto, H., Pavo, I. J., Klaushofer, K., & Paschalis, E. P. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2814-2 · Cited by 24
Bone-seeking agents for the treatment of bone disorders
Cawthray, J. F., Wasan, E. K., & Wasan, K. M. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0394-3 · Cited by 23
Effects of zoledronic acid on vertebral shape of children and adolescents with osteogenesis imperfecta
Li, L., Zheng, W., Zhao, D., Yu, W., Wang, O., Jiang, Y., Xia, W., & Li, M. (2019) · Bone · doi:10.1016/j.bone.2019.06.011 · Cited by 23
Naphthalimide-functionalized bisphosphonates for fluorescence detection of calcification in soft tissues
Oshchepkov, A. S., Oshchepkov, M., Pavlova, G. V., Ryabova, A. V., Kamagurov, S., Tkachenko, S., Frolova, S. I., Redchuk, A., Popov, K., & Kataev, E. A. (2020) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2020.128047 · Cited by 23
Solid-State Phase Transition Mechanism and Physical–Chemical Study of the Crystal Forms of Monosodium Alendronate: Trihydrate versus Anhydrate
Gonzaga, E. V., Viana, A. L. M., Viana, O. M. M. S., & Doriguetto, A. C. (2016) · Crystal Growth & Design · doi:10.1021/acs.cgd.6b01064 · Cited by 23
Bisphosphonate-incorporated coatings for orthopedic implants functionalization
Zhang, J., Bai, H., Bai, M., Wang, X., Li, Z., Xue, H., Wang, J., Cui, Y., Wang, H., Wang, Y., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100737 · Cited by 22
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday
Xu, L., ADAMS-HUET, B. A., POINDEXTER, J. R., & Maalouf, N. M. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3447-9 · Cited by 22
Composite Biomaterial as a Carrier for Bone-Active Substances for Metaphyseal Tibial Bone Defect Reconstruction in Rats
Horstmann, P. F., Raina, D. B., Isaksson, H., Hettwer, W. H., Lidgren, L., Petersen, M. M., & Tägil, M. (2017) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0040 · Cited by 22
Is there a role for bisphosphonates in vascular calcification in chronic kidney disease?
Hildebrand, S., & Cunningham, J. (2020) · Bone · doi:10.1016/j.bone.2020.115751 · Cited by 22
Development of Poly(Glycerol Sebacate) and Its Derivatives: A Review of the Progress over the past Two Decades
Liu, Y., Zeng, G., Xu, J., Han, M., Wang, Z., Li, T., Long, M., Wang, L., Huang, W., & Wu, Y. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2150774 · Cited by 23
Bisphosphonate conjugation enhances the bone-specificity of NELL-1-based systemic therapy for spaceflight-induced bone loss in mice
Ha, P., Kwak, J. H., Zhang, Y., Shi, J., Tran, L., Liu, T. P., Pan, H.-C., Lee, S., Kim, J. K., Chen, E., et al. (2023) · npj Microgravity · doi:10.1038/s41526-023-00319-7 · Cited by 21
Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis
Rizzoli, R. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09352920 · Cited by 22
Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys
Manabe, T., Mori, S., Mashiba, T., Cao, Y., Kaji, Y., Iwata, K., Komatsubara, S., Yamamoto, T., Seki, A., & Norimatsu, H. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0046-x · Cited by 22
The effects of zoledronate on the survival and function of human osteoblast-like cells
Huang, K., Cheng, C.-C., Chuang, P., & Yang, T. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0818-5 · Cited by 22
Treatment of osteoporotic intertrochanteric fractures by zoledronic acid injection combined with proximal femoral nail anti-rotation
Li, Y., Zhao, W., Wang, D., He, Q., Li, Q., Pei, F., & Liu, L. (2016) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2016.07.001 · Cited by 22
Assessment of bisphosphonate treated-osteoblast behaviors by conventional assays and a simple digital image analysis
Patntirapong, S., Chanruangvanit, C., Lavanrattanakul, K., & Satravaha, Y. (2020) · Acta Histochemica · doi:10.1016/j.acthis.2020.151659 · Cited by 22
Effect of bisphosphonates on macrophagic THP-1 cell survival in bisphosphonate-related osteonecrosis of the jaw (BRONJ)
Hoefert, S., Hoefert, C. S., Munz, A., Schmitz, I., Grimm, M. R., Yuan, A., Northoff, H., Reinert, S., & Alexander, D. (2015) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2015.10.008 · Cited by 22

Authors: Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H.
Affiliations: University at Buffalo, State University of New York (US)
Procter & Gamble (United States) (US)
Nuffield Orthopaedic Centre (GB)
Corresponding author: Ebetino, F.H.
ORCID: Tang, R.
Mangood, A.
Russell, R.G.G.
Ebetino, F.H.
Venue: Bone
Publisher: Elsevier BV
Published: 2006-05
Volume: 38
Issue: 5
Pages: 617-627
ISSN: 1873-2763 (ISSN-L)
8756-3282
DOI: 10.1016/j.bone.2005.05.003
OpenAlex: W2128778774
Cited by: 862
References: 75
Citations by year: 2026: 17 · 2025: 23 · 2024: 15 · 2023: 24 · 2022: 41 · 2021: 29 · 2020: 45 · 2019: 39 · 2018: 44 · 2017: 40 · 2016: 39 · 2015: 45 · 2014: 55 · 2013: 48 · 2012: 44
FWCI: 18.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Bone (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Dental and Craniofacial Research (DE03223)
National Institutes of Health
Topics: Health Sciences › Medicine › Oncology › Bone health and treatments
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords: bisphosphonates, hydroxyapatite, drug adsorption, binding affinity, crystal growth inhibition, zeta potential, interfacial tension, zoledronic acid, alendronate, ibandronate, risedronate, etidronate, clodronate, bone mineral, osteoporosis, duration of action, protein prenylation
MeSH terms: Bone and Bones, Crystallization, Diphosphonates, Humans, Stress, Mechanical, Durapatite, Bone Density Conservation Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks